AR021745A1 - Compuestos de sulfonamida utiles para potenciar la funcion de los glutamatoreceptores y composiciones farmaceuticas formuladas con dichos compuestos - Google Patents

Compuestos de sulfonamida utiles para potenciar la funcion de los glutamatoreceptores y composiciones farmaceuticas formuladas con dichos compuestos

Info

Publication number
AR021745A1
AR021745A1 ARP990103723A ARP990103723A AR021745A1 AR 021745 A1 AR021745 A1 AR 021745A1 AR P990103723 A ARP990103723 A AR P990103723A AR P990103723 A ARP990103723 A AR P990103723A AR 021745 A1 AR021745 A1 AR 021745A1
Authority
AR
Argentina
Prior art keywords
alkyl
cycloalkyl
alkenyl
phenyl
group
Prior art date
Application number
ARP990103723A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR021745A1 publication Critical patent/AR021745A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/04—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/26—Radicals substituted by halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Se trata de compuestos de sulfonamida de formula (1) en la que: uno o ambos de Ra y Rb se seleccionan independientemente de F, CF3 y -ORc, siendo Rchidrogeno o alquilo C1-4, y cualquiera del resto hidrogeno; o Ra y Rb juntos representan =O o =CH2; R1representa un grupo naftilo o un grupo fenilo, furilo,tienilo o piridilo que no está sustituido o está sustituido por uno o dos sustituyentes seleccionados independientemente de halogeno; nitro; ciano;hidroxiimino; alquilo C1-10; alquenilo C2-10; alquinilo C2-10; cicloalquilo C3-8; hidroxi(cicloalquilo C3-8); oxo(cicloalquilo C3-8); halo(alquilo C1-10);(CH2)yX1R9, donde y es 0 o un entero de 1 a 4; X1 representa O, S, NR10, CO, COO, OCO, CONR11, NR12CO, NR12COCOO u OCONR13; R9 representa hidrogeno, alquiloC1-10, alquenilo C3-10, alquinilo C3-10, pirrolidinilo, tetrahidrofurilo, morfolino o cicloalquilo C3-8 y cada uno de R10, R11, R12 y R13 representaindependientemente hidrogeno o alquilo C1-10, o R9 y R10, R11, R12 o R13 junto con el átomo de nitrogeno al que están unidos forman un grupo azetidinilo,pirrolidinilo, piperidinilo o morfolino; N-(alquil C1-4)piperazinilo; N-fenil(alquil C1-4)piperazinilo; tienilo; furilo; oxazolilo; isoxazolilo; pirazolilo;imidazolilo; tiazolilo; piridilo; piridazinilo; pirimidinilo; dihidrotienilo; dihidrofurilo; dihidrotiopiranilo; dihidropiranilo; dihidrotiazolilo;(alcoxi C1-4)-carbonildihidrotiazolilo; (alcoxi C1-4)-carbonildimetildihidrotiazolilo; tetrahidrotienilo; tetrahidrofurilo; tetrahidrotiopiranilo;tetrahidropiranilo; indolilo; benzofurilo; benzotienilo; bencimidazolilo; y un grupo de formula R14-(La)n-X2-(Lb)m en el que X2 representa un enlace, O, NH, S,SO, SO2, CO, CH(OH), CONH, NHCO, NHCONH, NHCOO, COCONH, OCH2CONH o CH=CH, La yLb representan cada uno alquileno C1-4, uno de n y m es 0 o 1 y el otro es 0, yR14 representa un grupo fenilo o heteroaromático que no está sustituido o está sustituido por uno o dos de halogeno, nitro, ciano, hidroxiimino, alquilo C1-10,alquenilo C2-10, alquinilo C2-10, cicloalquilo C3-8, 4-(1,1-dioxotetrahidro-1,2-tiazinilo), halo(alquilo C1-10), ciano(alquenilo C2-10), fenilo y (CH2)zX3R15,
ARP990103723A 1998-07-31 1999-07-28 Compuestos de sulfonamida utiles para potenciar la funcion de los glutamatoreceptores y composiciones farmaceuticas formuladas con dichos compuestos AR021745A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9490598P 1998-07-31 1998-07-31

Publications (1)

Publication Number Publication Date
AR021745A1 true AR021745A1 (es) 2002-08-07

Family

ID=22247857

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990103723A AR021745A1 (es) 1998-07-31 1999-07-28 Compuestos de sulfonamida utiles para potenciar la funcion de los glutamatoreceptores y composiciones farmaceuticas formuladas con dichos compuestos

Country Status (9)

Country Link
EP (1) EP0980864A3 (es)
JP (1) JP2002521443A (es)
AR (1) AR021745A1 (es)
AU (1) AU5239799A (es)
CA (1) CA2338864A1 (es)
CO (1) CO5080788A1 (es)
PE (1) PE20000944A1 (es)
SV (1) SV1999000115A (es)
WO (1) WO2000006157A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9702194D0 (en) 1997-02-04 1997-03-26 Lilly Co Eli Sulphonide derivatives
US6693137B1 (en) 1998-07-31 2004-02-17 Eli Lilly And Company Sulphonamide derivatives
BR0010183A (pt) 1999-04-30 2002-01-08 Lilly Co Eli Derivados de monofluoroalquila
WO2001089510A2 (en) * 2000-05-24 2001-11-29 Eli Lilly And Company Use of an ampa receptor potentiator for the treatment of obesity
EP1330233B1 (en) * 2000-10-13 2005-02-02 Eli Lilly And Company Method of treating stroke
US6900353B2 (en) 2000-10-13 2005-05-31 Eli Lilly And Company Cyclopentyl sulfonamide derivatives
AU2005270377A1 (en) * 2004-08-09 2006-02-16 Glaxo Group Limited Compounds which potentiate glutamate receptor and uses thereof in medicine
EP2417101B1 (en) * 2009-04-09 2013-10-23 Merck Sharp & Dohme B.V. Indane derivatives
WO2012075456A1 (en) 2010-12-02 2012-06-07 Constellation Pharmaceuticals Bromodomain inhibitors and uses thereof
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
US9422292B2 (en) 2011-05-04 2016-08-23 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
US9328117B2 (en) 2011-06-17 2016-05-03 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
US9624244B2 (en) 2012-06-06 2017-04-18 Constellation Pharmaceuticals, Inc. Benzo [B] isoxazoloazepine bromodomain inhibitors and uses thereof
BR112015031249A2 (pt) 2013-06-13 2017-07-25 Veroscience Llc método de tratamento, método para tratar um distúrbio metabólico ou um elemento chave do mesmo, método para normalizar um ritmo diário de liberação de dopamina no sumn, método para estimular a liberação de dopamina de neurônios dopaminérgicos no sumn de um indivíduo e composição farmacêutica
CN106687463B (zh) 2014-06-20 2019-04-09 星座制药公司 一种乙酰胺类化合物的晶型

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4876346A (en) * 1985-05-02 1989-10-24 American Home Products Corporation Quinoline compounds
EP0325245B1 (en) * 1988-01-19 1993-10-20 Tanabe Seiyaku Co., Ltd. Phenoxyacetic acid derivatives, preparation thereof, pharmaceutical compositions comprising them and use
DE3819052A1 (de) * 1988-06-04 1989-12-07 Basf Ag Neue sulfonamid-derivate, ihre herstellung und verwendung
DE4114330A1 (de) * 1991-05-02 1992-11-05 Basf Ag Neue arzneimittelkombination
GB9702194D0 (en) * 1997-02-04 1997-03-26 Lilly Co Eli Sulphonide derivatives

Also Published As

Publication number Publication date
EP0980864A3 (en) 2003-07-09
CO5080788A1 (es) 2001-09-25
PE20000944A1 (es) 2000-09-20
SV1999000115A (es) 2000-04-11
JP2002521443A (ja) 2002-07-16
AU5239799A (en) 2000-02-21
CA2338864A1 (en) 2000-02-10
WO2000006157A1 (en) 2000-02-10
EP0980864A2 (en) 2000-02-23

Similar Documents

Publication Publication Date Title
AR021745A1 (es) Compuestos de sulfonamida utiles para potenciar la funcion de los glutamatoreceptores y composiciones farmaceuticas formuladas con dichos compuestos
CO5080795A1 (es) Derivados de amida, carbamato y urea
AR030279A1 (es) Derivados de fenilamida para-amino sustituida activadora de la glucoquinasa, un procedimiento para su preparacion, composiciones farmaceuticas y el empleo de dichos derivados para la preparacion de medicamentos.
AR056582A1 (es) COMPUESTOS DE PIRAZOLIL UREA CON ACTIVIDAD INHIBITORIA DE CINASA P38 Y FORMULACIoN FARMACÉUTICA QUE LO COMPRENDE
EP0714299A4 (es)
AR043059A1 (es) Derivados de indolil pirazinona utiles para el tratamiento de trastornos hiper-proliferativos
CA2230936A1 (en) 5-azabicyclo(3.1.0)hexylalkyl-2-piperidones and -glutarimides as neurokinin receptor antagonists
CO5380013A1 (es) Compuestos de amina ciclica, su produccion y su uso
PE20020220A1 (es) Compuestos de nitrilo de dipeptido como inhibidores de catepsina k
AR035497A1 (es) Compuestos no-imidazol, composicion farmaceutica que los comprenden y el uso de los mismos para la preparacion de medicamentos
AR032453A1 (es) Derivados alquinil fenil heteroaromaticos activadores de glucoquinasa, un proceso para su preparacion, composiciones farmaceuticas, el uso de dichos derivados para la preparacion de medicamentos
AR066669A1 (es) Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas.
KR870011129A (ko) 디스타마이신 a 동족체 및 이의 제조방법
ES2175925T3 (es) Compuestos 4-(2-ceto-1-benzilimidazolinil)piperidina como agonistas del receptor orl1.
MEP10709A (en) 2-ARYL-6-PHENYLIMIDAZO[1,2-alpha]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
MEP22008A (en) Derivatives of n-[heteroaryl(piperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics
DK0402644T3 (da) N-(Aryloxyalkyl)-heteroarylpiperidiner og -heteroarylpiperaziner, fremgangsmåde til deres fremstilli ng samt deres anvendelse som medikamenter
CA2405046A1 (en) Stabilized pharmaceutical compositions comprising a calcium blocker and an alkaline material
AU7037298A (en) Certain cyclic thio substituted acylaminoacid amide derivatives
DK249089A (da) Benzamid-forbindelser, der er nyttige som protease-inhibitorer
EA200500087A1 (ru) Производные пиперазина
WO2004000762A3 (en) Propionic acid derivatives and their use as hppars activators
AR017127A1 (es) Nuevos compuestos de piperazina y piperidina, un metodo para su preparacion, composiciones farmaceuticas que las contienen, metodos para prepararlas y nuevos compuestos intermedios para dicho metodo.
SE8503415L (sv) Nya isoindolinylalkylpiperaziner och farmaceutiska kompositioner innehallande desamma
EA200700891A1 (ru) Производные пиридина, их получение и их применение в терапии